The FDA will now allow food labels to claim products have “no artificial colors” as long as they avoid petroleum-based dyes.

Among children younger than 2, the preventive effects of nirsevimab against RSV were maintained for up to 12 months after administration.

The table below is a review of notable updates that occurred in January 2026 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

COVID-19 infection prevention measures in NICUs significantly reduced viral HAIs but not bacterial or fungal rates.

For HPV testing for detection of cervical intraepithelial neoplasia grade 2/3 or worse, minipad-collected menstrual blood shows comparable diagnostic accuracy.

Another major medical group says most gender-related surgeries for minors in the U.S. should be postponed until adulthood.

Implementing weekly, high-risk rounds in the pediatric intensive care unit reduces the risk for hospital-acquired conditions.

Study data presented at ACTRIMS 2026 suggests clinical MS onset may precede laboratory-confirmed primary EBV infection in some patients.

A comprehensive review found no evidence to support the changes made by the CDC to the recommendations for hepatitis B vaccination in children.

Structured public health referral programs like CureTB help sustain treatment continuity for patients with tuberculosis relocating internationally.

Young adults with childhood-onset complex chronic conditions have longer acute care medical hospitalizations, higher costs, and higher readmission rates.

A phase 3 trial finds pritelivir significantly improves cure rates for immunocompromised individuals with refractory HSV infections.